JP2017531640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531640A5 JP2017531640A5 JP2017517662A JP2017517662A JP2017531640A5 JP 2017531640 A5 JP2017531640 A5 JP 2017531640A5 JP 2017517662 A JP2017517662 A JP 2017517662A JP 2017517662 A JP2017517662 A JP 2017517662A JP 2017531640 A5 JP2017531640 A5 JP 2017531640A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- mutated amino
- antigen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 238000000034 method Methods 0.000 claims 20
- 210000001744 T-lymphocyte Anatomy 0.000 claims 16
- 108091008874 T cell receptors Proteins 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 8
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108010063738 Interleukins Proteins 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000013642 negative control Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000003501 co-culture Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/058796 WO2016053338A1 (en) | 2014-10-02 | 2014-10-02 | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020066108A Division JP2020143057A (ja) | 2020-04-01 | 2020-04-01 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531640A JP2017531640A (ja) | 2017-10-26 |
| JP2017531640A5 true JP2017531640A5 (enExample) | 2017-12-07 |
| JP6686008B2 JP6686008B2 (ja) | 2020-04-22 |
Family
ID=51871270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517662A Active JP6686008B2 (ja) | 2014-10-02 | 2014-10-02 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20170218042A1 (enExample) |
| EP (2) | EP4074333A1 (enExample) |
| JP (1) | JP6686008B2 (enExample) |
| CN (2) | CN107074932A (enExample) |
| AU (3) | AU2014407539B2 (enExample) |
| CA (1) | CA2963362A1 (enExample) |
| DK (1) | DK3200818T3 (enExample) |
| ES (1) | ES2924709T3 (enExample) |
| WO (1) | WO2016053338A1 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3154350B1 (en) | 2014-04-10 | 2024-03-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| EP3848456A1 (en) | 2014-10-02 | 2021-07-14 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of isolating t cells having antigenic specificity for a cancer-specific mutation |
| EP3075389A1 (en) * | 2015-03-31 | 2016-10-05 | Technische Universität München | T cell receptors and peptides derived by mutations for the treatment of cancer |
| AU2016258845B2 (en) | 2015-05-01 | 2022-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
| WO2017048614A1 (en) | 2015-09-15 | 2017-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood |
| CA3030156A1 (en) | 2016-07-07 | 2018-01-11 | Iovance Biotherapeutics, Inc. | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| GB2604416B (en) | 2016-10-18 | 2023-03-15 | Univ Minnesota | Tumor infiltating lymphocytes and methods of therapy |
| KR20190066073A (ko) | 2016-10-26 | 2019-06-12 | 이오반스 바이오테라퓨틱스, 인크. | 냉동보존된 종양 침윤 림프구의 재자극 |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| KR102618948B1 (ko) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법 |
| US11357841B2 (en) | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| AU2018244371B2 (en) * | 2017-03-31 | 2025-04-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating neoantigen-specific T cell receptor sequences |
| WO2018215936A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| CN111201237B (zh) | 2017-09-20 | 2025-03-25 | 美国卫生和人力服务部 | 针对突变的ras的hlaii类限制性t细胞受体 |
| KR20250024096A (ko) * | 2017-09-29 | 2025-02-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 돌연변이된 p53을 인식하는 t 세포 수용체 |
| SG11202002635RA (en) | 2017-09-29 | 2020-04-29 | The United States Of America As Represented By The Secretary | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation |
| AU2018346765B2 (en) * | 2017-10-06 | 2025-02-06 | Oncotherapy Science, Inc. | Screening of T lymphocytes for cancer-specific antigens |
| CR20200251A (es) * | 2017-11-17 | 2020-07-17 | Iovance Biotherapeutics Inc | Expansión de til de aspirados con aguja fina y biopsias por punción |
| WO2019112932A1 (en) | 2017-12-04 | 2019-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells |
| WO2019118873A2 (en) * | 2017-12-15 | 2019-06-20 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
| US12104172B2 (en) | 2018-01-08 | 2024-10-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific t-cells |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| US12415845B2 (en) | 2018-04-24 | 2025-09-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof |
| KR20210005138A (ko) | 2018-04-27 | 2021-01-13 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 확장 및 유전자 편집을 위한 폐쇄 방법 및 면역요법에서의 그의 용도 |
| US12473532B2 (en) | 2018-05-10 | 2025-11-18 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN110857319B (zh) * | 2018-08-24 | 2023-12-08 | 杭州康万达医药科技有限公司 | 一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用 |
| CN109136183A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种rff2细胞的构建方法 |
| CN109136280A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种lrfft1细胞的构建方法 |
| CN109294998B (zh) * | 2018-09-30 | 2020-11-06 | 北京鼎成肽源生物技术有限公司 | 一种rff1细胞 |
| CN109294997B (zh) * | 2018-09-30 | 2020-09-25 | 北京鼎成肽源生物技术有限公司 | 一种lrfft1细胞 |
| CN109136278B (zh) * | 2018-09-30 | 2020-09-29 | 北京鼎成肽源生物技术有限公司 | 一种mrfft1细胞 |
| CN109295097B (zh) * | 2018-09-30 | 2020-09-25 | 北京鼎成肽源生物技术有限公司 | 一种mrfft2细胞 |
| CN110093373B (zh) * | 2018-09-30 | 2021-05-07 | 北京鼎成肽源生物技术有限公司 | 一种afft2细胞的构建方法 |
| CN109679917B (zh) * | 2018-09-30 | 2020-09-25 | 北京鼎成肽源生物技术有限公司 | 一种lrfft2细胞 |
| CN109294982B (zh) * | 2018-09-30 | 2020-11-06 | 北京鼎成肽源生物技术有限公司 | 一种rff2细胞 |
| CN109294983A (zh) * | 2018-09-30 | 2019-02-01 | 北京鼎成肽源生物技术有限公司 | 一种lff2细胞 |
| CN109136284B (zh) * | 2018-09-30 | 2020-12-29 | 北京鼎成肽源生物技术有限公司 | 一种afft2细胞 |
| CN109136269A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种aff细胞 |
| CN110093316A (zh) * | 2018-09-30 | 2019-08-06 | 北京鼎成肽源生物技术有限公司 | 一种aff细胞的构建方法 |
| CN109136268A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种lrff细胞的构建方法 |
| CN109136279A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种mrfft2细胞的构建方法 |
| CN109136277A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种lrfft2细胞的构建方法 |
| CN110093317A (zh) * | 2018-09-30 | 2019-08-06 | 北京鼎成肽源生物技术有限公司 | 一种lff2细胞的构建方法 |
| CN109136281A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种mrfft1细胞的构建方法 |
| TW202039830A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 |
| KR20210152464A (ko) | 2019-02-19 | 2021-12-15 | 미스트 쎄라퓨틱스, 엘엘씨 | 암 치료에 유용한 자가 t 세포의 제조 방법 및 그의 조성물 |
| AU2020231693A1 (en) * | 2019-03-04 | 2021-09-30 | University Health Network | T cell receptors and methods of use thereof |
| CN111748028A (zh) * | 2019-03-29 | 2020-10-09 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| CN111748029B (zh) * | 2019-03-29 | 2022-12-13 | 苏州蓝马医疗技术有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| CN111748027A (zh) * | 2019-03-29 | 2020-10-09 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| CN111848782A (zh) * | 2019-04-25 | 2020-10-30 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| EP3990011A4 (en) * | 2019-06-24 | 2023-11-01 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | PEPTIDE-BASED SCREENING METHOD FOR IDENTIFYING NEO-ANTIGENS FOR USE WITH TUMOR-INFILTRATING LYMPHOCYTES |
| US20220331360A1 (en) | 2019-08-07 | 2022-10-20 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | T cells having enhanced anti-tumor activity |
| JP2023504042A (ja) | 2019-11-27 | 2023-02-01 | ミスト セラピューティクス リミテッド ライアビリティ カンパニー | 調節物質を使用した腫瘍反応性ｔ細胞組成物の生成方法 |
| CN111019959B (zh) * | 2019-12-30 | 2022-09-13 | 北京立康生命科技有限公司 | 一种体外转录mRNA的核苷酸分子、呈递细胞及应用 |
| BR112022016490A2 (pt) | 2020-02-27 | 2022-10-11 | Myst Therapeutics Llc | Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas |
| EP4121513A1 (en) | 2020-03-20 | 2023-01-25 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods of isolating t cells and t-cell receptors from peripheral blood by single-cell analysis for immunotherapy |
| WO2021188954A1 (en) | 2020-03-20 | 2021-09-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy |
| BR112022021020A2 (pt) | 2020-04-22 | 2023-02-14 | Iovance Biotherapeutics Inc | Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celular |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CN112133372B (zh) * | 2020-08-18 | 2022-06-03 | 北京臻知医学科技有限责任公司 | 抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法 |
| AU2021341969A1 (en) | 2020-09-08 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell phenotypes associated with response to adoptive cell therapy |
| WO2022086185A1 (ko) * | 2020-10-20 | 2022-04-28 | 연세대학교 산학협력단 | 단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법 |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| WO2024098041A1 (en) * | 2022-11-04 | 2024-05-10 | Turnstone Biologics Corp. | Compositions and methods for generating neo-antigen reactive tumor infiltrating lymphocytes |
| WO2025080865A1 (en) | 2023-10-11 | 2025-04-17 | Turnstone Biologics Corp. | Combination of tumor infiltrating lymphocytes (til) and low dose radiation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| US8486694B2 (en) * | 2005-08-05 | 2013-07-16 | Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH | Generation of antigen specific T cells |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US9211321B2 (en) * | 2009-10-27 | 2015-12-15 | Immunicum Ab | Method for proliferation of antigen-specific T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| AU2012309830B2 (en) * | 2011-09-15 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage |
| JP6126804B2 (ja) * | 2012-07-25 | 2017-05-10 | 国立大学法人富山大学 | Ｔ細胞受容体のクローニング方法 |
| EP2892544A4 (en) * | 2012-09-05 | 2016-11-02 | Univ Virginia Patent Found | TARGET PEPTIDES FOR THERAPY AND DIAGNOSIS OF COLORECTAL CARCINOMAS |
| PT2895509T (pt) * | 2012-09-14 | 2020-03-13 | Us Health | Recetores de células t que reconhecem mage-3 restrito a mhc de classe ii |
| EP2961415B1 (en) * | 2013-03-01 | 2021-01-06 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor-reactive t cells from tumor |
| EP3628322A1 (en) * | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
-
2014
- 2014-10-02 ES ES14796317T patent/ES2924709T3/es active Active
- 2014-10-02 CA CA2963362A patent/CA2963362A1/en active Pending
- 2014-10-02 JP JP2017517662A patent/JP6686008B2/ja active Active
- 2014-10-02 WO PCT/US2014/058796 patent/WO2016053338A1/en not_active Ceased
- 2014-10-02 AU AU2014407539A patent/AU2014407539B2/en active Active
- 2014-10-02 US US15/514,942 patent/US20170218042A1/en not_active Abandoned
- 2014-10-02 CN CN201480082932.3A patent/CN107074932A/zh active Pending
- 2014-10-02 EP EP22166152.3A patent/EP4074333A1/en active Pending
- 2014-10-02 DK DK14796317.7T patent/DK3200818T3/da active
- 2014-10-02 CN CN202411616177.4A patent/CN119409799A/zh active Pending
- 2014-10-02 EP EP14796317.7A patent/EP3200818B1/en active Active
-
2021
- 2021-01-21 AU AU2021200388A patent/AU2021200388B2/en active Active
-
2022
- 2022-12-29 US US18/147,786 patent/US20230203124A1/en active Pending
-
2023
- 2023-12-12 AU AU2023282185A patent/AU2023282185A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531640A5 (enExample) | ||
| IL273516B2 (en) | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation | |
| JP2020534839A5 (enExample) | ||
| Elyada et al. | Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts | |
| Chen et al. | Transcriptional and epigenetic regulation of effector and memory CD8 T cell differentiation | |
| Hussain et al. | Similar but different: virtual memory CD8 T cells as a memory‐like cell population | |
| Böttcher et al. | Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity | |
| Ohne et al. | IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity | |
| Guia et al. | Helper-like innate lymphoid cells in humans and mice | |
| Maynard et al. | Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulation | |
| Jung et al. | Differential localization of effector and memory CD8 T cell subsets in lymphoid organs during acute viral infection | |
| Yang et al. | The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets | |
| Hale et al. | Distinct memory CD4+ T cells with commitment to T follicular helper-and T helper 1-cell lineages are generated after acute viral infection | |
| Martin et al. | Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity? | |
| ES2957959T3 (es) | Métodos de aislamiento de secuencias de receptores de células T específicos de neoantígenos | |
| CN104087592B (zh) | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 | |
| Patil et al. | The Jekyll and Hyde story of IL17-producing γδT cells | |
| JP2016509840A5 (enExample) | ||
| WO2014017533A1 (ja) | T細胞受容体のクローニング方法 | |
| JP7211945B2 (ja) | ヒト自然リンパ球前駆細胞：同定、特性評価、応用 | |
| Ventre et al. | Negative regulation of NKG2D expression by IL-4 in memory CD8 T cells | |
| JP2018529339A5 (enExample) | ||
| Brinza et al. | Immune signatures of protective spleen memory CD8 T cells | |
| Mora-Buch et al. | Discipline in stages: regulating CD8+ resident memory T cells | |
| Kerkar et al. | Timing and intensity of exposure to interferon‐γ critically determines the function of monocyte‐derived dendritic cells |